Cardiovascular manifestations in severe and critical patients with <scp>COVID</scp>‐19

Chen, Qingxing; Xu, Lili; Zhu, Wenqing; Ge, Junbo

doi:10.1002/clc.23422

Cited by 36 publications

(59 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chen et al 4 compared cardiovascular system variables in a small number of severely sick (39 cases) and critically sick (15 cases) COVID-19 patients, and found that diabetes, significant leukocytosis, elevated level of inflammatory elements (interleukin-6, C-reactive protein, erythrocyte sedimentation rate, D-dimer, and procalcitonin), elevated markers of myocardial injury (CK-MB, troponin-I, myoglobin, and proBNP), hypotension and tachycardia at admission, atrioventricular block, pericardial effusion, and right heart block were more prevalent in critically-ill patients.…”

Section: Discussionmentioning

confidence: 99%

“…As the pandemic of coronavirus disease 19 (COVID-19), caused by the severe acute respiratory syndrome novel coronavirus 2 (SARS-CoV-2), is evolving, an increasing number of studies are pointing to the relationship of cardiovascular disease with mortality in hospitalized patients. 1 , 2 , 3 , 4 , 5 Most previously published studies on this subject consist of small-to-large series of patients who had or developed cardiovascular events as a result of infection with SARS-CoV-2. However, few studies have compared the presence of cardiovascular disease risk factors, its manifestations, and related laboratory parameters with regard to mortality in patients with COVID-19.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19

Shoar

Hosseini

Naderan

et al. 2020

The American Journal of Cardiology

View full text Add to dashboard Cite

Since the emergence of the coronavirus disease 19 (COVID-19), a number of studies have reported the presence of cardiovascular diseases in affected patients and linked them with a higher risk of mortality. We conducted an online search in Medline/PubMed to identify original cohorts comparing data between survivors and non-survivors from COVID-19. The presence of cardiovascular events and related biomarkers were compared between the 2 groups. Data on 1,845 hospitalized patients with COVID-19 were pooled from 12 comparative studies. The overall mortality rate in relation to COVID-19 was 17.6%. Men aged > 50 years old were more likely to die from COVID-19. Significant co-morbidities contributing to mortality were hypertension, diabetes mellitus, smoking, a previous history of cardiovascular disease including chronic heart failure, and cerebrovascular accidents. A significant relationship was observed between mortality and patient presentation with dyspnea, fatigue, tachycardia, and hypoxemia. Cardiovascular disease-related laboratory biomarkers related to mortality were elevated serum level of lactate dehydrogenase, creatine kinase, brain natriuretic peptide, and cardiac troponin I. Adverse cardiovascular disease-related clinical events preceding death were shock, arrhythmias, and acute myocardial injury. In conclusion, severe clinical presentation and elevated biomarkers in COVID-19 patients with established risk factors can predict mortality from cardiovascular causes. Published by Elsevier Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19

Shoar

Hosseini

Naderan

et al. 2020

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…Concerns of cardiac outcomes in COVID-19 patients have been highlighted relating to worst outcomes in severely symptomatic and critically ill patients of COVID-19, with the most frequent presentation of hypotension, sinus tachycardia, arteriovenous block, ventricular tachycardia, pericardial effusion, and heart failure [ 4 ]. However, pericardial involvement is rare with the therapeutic challenge.…”

Section: Discussionmentioning

confidence: 99%

Acute Pericarditis and Pericardial Effusion in a Hypertensive COVID-19 Patient

Naqvi¹,

Naseeb²,

Fatima³

et al. 2020

Cureus

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a contagious disease that has a potential of causing cardiovascular illness. Cardiac outcomes of COVID-19 mainly include acute coronary syndrome, heart failure, and left ventricular dysfunction. However, pericardial involvement is very rare. Here, we present a case of pericarditis and pericardial effusion in a known hypertensive COVID-19 patient. Our case was a diagnostic dilemma as the literature review mentioned that cardiovascular manifestations are mostly reported in symptomatic and critically ill patients of COVID-19. However, this patient has no viral respiratory illness, and is otherwise healthy.

show abstract

“…However, reliable data regarding first-diagnosed AF in patients with COVID-19 are limited. Based on case reports [19] , [20] and small clinical studies [21] , [22] , [23] , [24] , new-onset AF varies between 3.6% and 6.7% in patients with COVID-19.…”

Section: Prevalence Of Af In Patients With Covid-19mentioning

confidence: 99%

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Gawałko

Kapłon‐Cieślicka

Hohl

et al. 2020

IJC Heart & Vasculature

131

142

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients.

show abstract

Cardiovascular manifestations in severe and critical patients with COVID‐19

Abstract: To the editor, We would like to thank Kosuke Miki and Teruhiko Imamura for their thoughtful comments regarding our article titled "Cardiovascular Manifestations in Severe and Critical Patients with COVID-19," which was published last month in Clinical Cardiology.

Cited by 36 publications

References 0 publications

Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19

Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19

Acute Pericarditis and Pericardial Effusion in a Hypertensive COVID-19 Patient

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Contact Info

Product

Resources

About